Literature DB >> 34306488

The combined detection of autoantibody characteristics in systemic lupus erythematosus.

Weichen Wang1, Hongmei Gao1.   

Abstract

OBJECTIVE: To investigate the combined detection of the autoantibody characteristics in systemic lupus erythematosus (SLE).
METHODS: 105 SLE patients admitted to our hospital from May 2019 to September 2020 were placed in the SLE examination group (the SE group), 110 patients with rheumatic diseases admitted to our hospital during the same period were placed in the disease control group (the DC group), and 100 healthy people who came to our hospital for physical examinations during the same time period were placed in the healthy control group (the HC group). The SLE patients' clinical data were recorded. The patients' antinuclear antibody (ANA), anti-dsDNA, anti-SM, anti-SSA, and anti-rRnp levels were measured.
RESULTS: There were no significant differences in the occurrences of fever, alopecia, photosensitivity, interstitial lung disease, Raynaud's phenomenon, pulmonary arterial hypertension, or osteoporosis. (P > 0.05), but there were higher incidences of arthralgia and butterfly erythema in the female patients (P < 0.05), and higher incidences of renal damage, oral ulcers, nervous system damage, and dysopsia in the male patients (P < 0.05). The positive autoantibody rate in the SE group was significantly higher than it was in the DC and HC groups (P < 0.05). A logistic regression analysis showed that the anti-SM, anti-dsDNA, AnuA, and anti-SSA levels entered the regression equation with statistical differences when P < 0.05. Among the four autoantibodies, the anti-SSA sensitivity was the highest, but its specificity was the lowest, and the specificities of the other three autoantibodies were all more than 97%. The positive rate of anti-dsDNA in its active stage was higher than it was in its inactive stage (P < 0.05). The positive rates of AnuA and anti-SM in their active stages was higher than they were in their inactive stages (P > 0.05). The sensitivities of the combined measurements were higher than the single autoantibody measurements (P < 0.05).
CONCLUSION: Single autoantibody detection has the disadvantage of low sensitivity or specificity. The combined detection of autoantibodies can effectively improve the sensitivity and specificity of SLE detection, so it is worthy of clinical promotion. AJTR
Copyright © 2021.

Entities:  

Keywords:  Systemic lupus erythematosus (SLE); autoantibody characteristics; combined detection of autoantibodies; diagnostic value

Year:  2021        PMID: 34306488      PMCID: PMC8290698     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  25 in total

Review 1.  Systemic lupus erythematosus.

Authors:  Arvind Kaul; Caroline Gordon; Mary K Crow; Zahi Touma; Murray B Urowitz; Ronald van Vollenhoven; Guillermo Ruiz-Irastorza; Graham Hughes
Journal:  Nat Rev Dis Primers       Date:  2016-06-16       Impact factor: 52.329

2.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

3.  Belimumab and antipneumococcal vaccination in patients with systemic lupus erythematosus.

Authors:  Tudor Azoicai; Sabina Antoniu; Irina Draga Caruntu; Doina Azoicai; Ileana Antohe; Cristina Gavrilovici
Journal:  Expert Rev Clin Immunol       Date:  2018-01-22       Impact factor: 4.473

4.  The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.

Authors:  Tineke Kraaij; Sylvia W A Kamerling; Esther N M de Rooij; Paul L A van Daele; Obbo W Bredewold; Jaap A Bakker; Ingeborg M Bajema; Hans U Scherer; Rene E M Toes; Tom J W Huizinga; Ton J Rabelink; Cees van Kooten; Y K Onno Teng
Journal:  J Autoimmun       Date:  2018-04-07       Impact factor: 7.094

5.  The safety of belimumab for the treatment of systemic lupus erythematosus.

Authors:  Leanna M Wise; William Stohl
Journal:  Expert Opin Drug Saf       Date:  2019-10-31       Impact factor: 4.250

6.  A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.

Authors:  Fengchun Zhang; Sang-Cheol Bae; Damon Bass; Myron Chu; Sally Egginton; David Gordon; David A Roth; Jie Zheng; Yoshiya Tanaka
Journal:  Ann Rheum Dis       Date:  2018-01-02       Impact factor: 19.103

7.  Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.

Authors:  A Doria; W Stohl; A Schwarting; M Okada; M Scheinberg; R van Vollenhoven; A E Hammer; J Groark; D Bass; N L Fox; D Roth; D Gordon
Journal:  Arthritis Rheumatol       Date:  2018-06-15       Impact factor: 10.995

8.  Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.

Authors:  Richard A Furie; Daniel J Wallace; Cynthia Aranow; James Fettiplace; Barbara Wilson; Prafull Mistry; David A Roth; David Gordon
Journal:  Arthritis Rheumatol       Date:  2018-04-25       Impact factor: 10.995

9.  Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.

Authors:  Ronald F van Vollenhoven; Sandra V Navarra; Roger A Levy; Mathew Thomas; Amy Heath; Todd Lustine; Anthony Adamkovic; James Fettiplace; Mei-Lun Wang; Beulah Ji; David Roth
Journal:  Rheumatology (Oxford)       Date:  2020-02-01       Impact factor: 7.580

Review 10.  Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New.

Authors:  Fabio Basta; Federica Fasola; Konstantinos Triantafyllias; Andreas Schwarting
Journal:  Rheumatol Ther       Date:  2020-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.